Primary aldosteronism as a systemic endocrine tumor disease: a severity-stratified framework for diagnosis, targeted treatment, and long-term surveillance

Primary aldosteronism (PA) is a systemic endocrine tumor disease driven by somatic-mutation-defined aldosterone-producing lesions. In most unilateral cases, adrenalectomy achieves biochemical cure and restores mortality to that of the general population. However, diagnostic delay, limited access to adrenal venous sampling (AVS) and specialized surgery, and bilateral or non-operable disease mean that many patients require lifelong pharmacological therapy and structured surveillance. This review proposes a severity-stratified framework for diagnosis, targeted treatment, and long-term surveillance around four pillars: (1) early and expanded screening, stratified by pretest probability and severity; (2) precision subtyping, with surgical candidacy and patient preference as the first decision node, integrated with probability-based pathways, Primary Aldosteronism Severity Classification (PASC) grading, molecular and genetic subtyping, and cortisol co-secretion screening; (3) targeted source elimination (adrenalectomy) or mineralocorticoid receptor (MR) blockade, with plasma renin reactivation proposed as a candidate pharmacodynamic marker rather than a validated endpoint; and (4) structured long-term surveillance, with basic assessments universal and advanced imaging reserved for high-risk patients or research protocols. For each pillar, we distinguish guideline-based recommendations from expert consensus and research-oriented components, and identify key evidence gaps. We critically appraise 2025–2026 guidelines and emerging evidence on molecular imaging, patient-reported outcomes, and novel agents. The framework translates pathophysiological insights into an actionable, organ-protection-centered pathway while remaining explicit about what is known, assumed, and still unproven; several components—renin-guided MR antagonist titration, AVS-bypass strategies, and advanced follow-up imaging—remain hypothesis-generating and require prospective validation.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-16
DOI
https://doi.org/10.3389/fendo.2026.2023718
Primary Topic
Hormonal Regulation and Hypertension
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Primary aldosteronism as a systemic endocrine tumor disease: a severity-stratified framework for diagnosis, targeted treatment, and long-term surveillance

Haiye Fan, Jiaqiang Gui, Yue Wang, Xiaofeng Zou et al.
4 links
Frontiers in Endocrinology
Hormonal Regulation and Hypertension
article

Primary aldosteronism as a systemic endocrine tumor disease: a severity-stratified framework for diagnosis, targeted treatment, and long-term surveillance

Haiye Fan, Jiaqiang Gui, Yue Wang, Xiaofeng Zou, Tianpeng Xie, Jianxin Gong
article en

Abstract

Primary aldosteronism (PA) is a systemic endocrine tumor disease driven by somatic-mutation-defined aldosterone-producing lesions. In most unilateral cases, adrenalectomy achieves biochemical cure and restores mortality to that of the general population. However, diagnostic delay, limited access to adrenal venous sampling (AVS) and specialized surgery, and bilateral or non-operable disease mean that many patients require lifelong pharmacological therapy and structured surveillance. This review proposes a severity-stratified framework for diagnosis, targeted treatment, and long-term surveillance around four pillars: (1) early and expanded screening, stratified by pretest probability and severity; (2) precision subtyping, with surgical candidacy and patient preference as the first decision node, integrated with probability-based pathways, Primary Aldosteronism Severity Classification (PASC) grading, molecular and genetic subtyping, and cortisol co-secretion screening; (3) targeted source elimination (adrenalectomy) or mineralocorticoid receptor (MR) blockade, with plasma renin reactivation proposed as a candidate pharmacodynamic marker rather than a validated endpoint; and (4) structured long-term surveillance, with basic assessments universal and advanced imaging reserved for high-risk patients or research protocols. For each pillar, we distinguish guideline-based recommendations from expert consensus and research-oriented components, and identify key evidence gaps. We critically appraise 2025–2026 guidelines and emerging evidence on molecular imaging, patient-reported outcomes, and novel agents. The framework translates pathophysiological insights into an actionable, organ-protection-centered pathway while remaining explicit about what is known, assumed, and still unproven; several components—renin-guided MR antagonist titration, AVS-bypass strategies, and advanced follow-up imaging—remain hypothesis-generating and require prospective validation.

Frontiers in EndocrinologyVol. 17
First Affiliated Hospital of Gannan Medical University (CN)
Health Commission of Jiangxi Province, Gannan Medical University
Good health and well-being
Hormonal Regulation and Hypertension
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon